Search Results - oncology

19 Results Sort By:
Anti-Cancer Maleimide Derivatives for Use with Immune Checkpoint Blockade
Overview We have invented a cancer treatment that consists of administering an anti-cancer maleimide derivative together with an immune checkpoint blockade. Market Opportunity Globally, colorectal cancer (CRC) ranks third in incidence and second in mortality. The U.S. Food and Drug Administration recently approved the checkpoint inhibitors nivolumab...
Published: 6/7/2023   |   Inventor(s): Wafik El-Deiry, Kelsey Huntington
Category(s): Therapeutics, Oncology
Treating Glioblastoma, Metastatic Melanoma, and Other Tumors Involving CNS Metastases
Overview Metastasis involving the spread of systemic cancer to the brain typically results in neurologic disability and death; current treatments are largely palliative in nature. We have invented a method of treatment based on determining whether the patient has an increased level of MDM2/MDM4 genes and/or proteins and/or a decreased level of CDKN2A...
Published: 6/7/2023   |   Inventor(s): Wafik El-Deiry, Taylor Arnoff
Category(s): Diagnostics, Therapy Targets, Oncology
Inhibition of FTO with Entacapone to Treat Glioblastoma
Overview Glioblastoma is one of the most aggressive and lethal human tumors. We are investigating the use of an FDA-approved drug, Entacapone, to treat glioma tumors. Market Opportunity Glioblastoma, one of the most aggressive forms of cancer, has a survival rate of only 14–15 months after diagnosis. There is an urgent need for effective therapies...
Published: 10/15/2022   |   Inventor(s): Nikolaos (Nikos) Tapinos, John Zepecki, David Karambizi
Category(s): Oncology, Therapeutics
HDAC-7 as novel therapeutic target for human glioblastoma
Overview Glioblastoma is one of the most aggressive and lethal human tumors. We have identified histone deacetylase 7 (HDAC-7) as a potential therapeutic target, a crucial first step toward development of an effective treatment for glioblastoma. Market Opportunity Glioblastoma is the most malignant and aggressive primary brain tumor, with a survival...
Published: 10/15/2022   |   Inventor(s): Nikolaos (Nikos) Tapinos, Ola Hassan, David Karambizi
Category(s): Therapy Targets, Oncology
Small molecule CB002 and its analogs restore the p53 pathway and target an S-phase checkpoint
­Novel Class of Small Molecules Restores Important p53 Pathway Overview Approximately 50% of human cancers involve mutations in the tumor-suppressor gene p53, while the other 50% involve some type of inactivation on the p53 pathway. We have discovered a class of small molecules that restore the p53 pathway, as well as perturb an S-phase checkpoint. ...
Published: 2/22/2022   |   Inventor(s): Wafik El-Deiry, Liz Borrero
Category(s): Therapeutics, Oncology
Targeting enhancer RNAs (eRNA) for the treatment of primary brain tumors
­Novel Therapeutic Approach for Glioblastoma Overview Enhancer RNAs (eRNAs) are transcribed from active enhancer regions of the genome and function to increase the expression of target genes. The expression of specific eRNAs in glioma stem cells is correlated with decreased survival of patients with glioblastomas. Our novel technology uses synthetic...
Published: 2/22/2022   |   Inventor(s): Nikolaos (Nikos) Tapinos, Blessing Akobundu
Category(s): Therapeutics, Oncology
Inhibition of Glycogen Synthase Kinase 3-beta (GSK3-b) with the small molecule 9-ING-41 stimulates Natural Killer and T cell activity, reduces vascular endothelial growth factor levels, and induces cancer cell death.
­Overview In recent years, immune checkpoint blockade (ICB) has provided oncologists with a powerful new tool. But while ICB has been found to be effective in microsatellite instability-high (MSI-H) colorectal cancer, it is far less effective in microsatellite stable (MSS) colorectal cancer. We have developed glycogen synthase kinase-beta (GSK-3-b)...
Published: 2/8/2022   |   Inventor(s): Wafik El-Deiry, Kelsey Huntington, Benedito Carneiro
Category(s): Therapeutics, Oncology
Optogenetic Control of the Blood Brain Barrier for Drug Delivery (Case 2135)
Optogenetic Control of the Blood Brain Barrier for Drug Delivery Overview The blood–brain barrier (BBB) remains a significant impediment to drug development for central nervous system (CNS) disorders. Our novel method provides a way to regulate the permeability of the BBB, enabling delivery of therapeutics to the brain with high spatial and temporal...
Published: 4/28/2020   |   Inventor(s): Christopher Moore, Tyler Brown
Category(s): Engineering and Sensors, Drug Delivery, Neuroscience, Oncology, Therapeutics
Improved Method of Manufacturing Nanowire Nanoarray Memories (Case 1709)
Principal Investigator: John Savage, PhD, Professor Department of Computer ScienceBrown UniversityProvidence, RIBrief Description:Methods have been developed for growing nanowires (NWs) and carbon nanotubes (NTs) with diameters of a few nanometers and for assembling NWs into nanoarrays, crossbars containing two orthogonal sets of parallel wires on...
Published: 4/28/2020   |   Inventor(s): John Savage, Eric Rachlin, Andre Dehon, Charles Lieber
Category(s): Devices, Diagnostics, Engineering and Sensors, Environmental, Metabolic diseases, Nanotechnology, Neuroscience, Oncology, Research Tools, Software, Stem Cells and Regenerative Medicine
Optimized, Cost Effective X-Ray Imaging that Rivals MRI: X-Ray Spatial Frequency Heterodyne Imaging with Protein-Based “Nanobubble” Contrast Agents
Principal Investigator: Christoph Rose-Petruck, PhD, ProfessorDepartment of ChemistryBrown UniversityProvidence, RIBrief Description:Spatial Frequency Heterodyne Imaging (SFHI) is a novel x-ray scatter imaging technique that utilizes nanoparticle contrast agents. Previous studies on SFHI have utilized only metal nanoparticle contrast agents such as...
Published: 4/8/2020   |   Inventor(s): Christoph Rose-Petruck, Trevor Douglas, Danielle Rand, Masaki Uchida
Category(s): Diagnostics, Drug Delivery, Instruments, Nanotechnology, Oncology, Research Tools
1 2 
© 2024. All Rights Reserved. Powered by Inteum